Oragenics, Inc. (0A64.L)
| Previous close | 1.0788 |
| Open | 1.0509 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.0509 - 1.0509 |
| 52-week range | 1.0509 - 7.4500 |
| Volume | |
| Avg. volume | 357 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1420 |
| Earnings date | 09 Aug 2024 - 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireOragenics Improves Intranasal Drug Formulation for Treating Concussed Patients
Formulation designed to enhance brain uptakeSARASOTA, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has developed a new formulation for its novel neurosteroid. Oragenics’ lead drug candidate for concussion, ONP-002, is a new chemical entity (NCE) designed to target the brain through delivery into the nasal cavity and onward to the bra
- GlobeNewswire
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
The device is intended for initial treatment in the acute settingSARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has completed a prototype of its automated intranasal device for use in concussed patients who are initially confused, dazed or unconscious in the acute phase of injury. Oragenics’ lead drug candidate, ONP-002, is a
- GlobeNewswire
Oragenics, Inc. Announces Closing of Public Offering
SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its public offering of 1,100,000 shares of its common stock at an offering price of $1.00 per share. The gross proceeds of the offering are approximately $1.1 million before deducting placement agent fees and other estimated offering expenses payable by the Company. T
